Browse by author
Lookup NU author(s): Dr Charlie Tomson
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2023, The Author(s) under exclusive licence to Italian Society of Nephrology.Background: Impaired quality of life is common in patients with end-stage kidney disease. We report the baseline quality of life measures in participants from the PIVOTAL randomized controlled trial and the potential relationship with the primary outcome (all-cause mortality, myocardial infarction, stroke, and heart failure hospitalisation), and associations with key baseline characteristics. Methods: This was a post hoc analysis of 2141 patients enrolled in the PIVOTAL trial. Quality of life was measured using EQ5D index, Visual Analogue Scale, and the KD-QoL [Physical Component Score and Mental Component Score]. Results: Mean baseline EQ5D index and visual analogue scale scores were 0.68 and 60.7 and 33.7 (Physical Component Score) and 46.0 (Mental Component Score), respectively. Female sex, higher Body Mass Index, diabetes mellitus, history of myocardial infarction, stroke or heart failure were associated with significantly worse EQ5D index and visual analogue scale. Higher C-reactive protein levels and lower transferrin saturation were associated with worse quality of life. Haemoglobin was not an independent predictor of quality of life. A lower transferrin saturation was an independent predictor of worse physical component score. A higher C-reactive protein level was associated with most aspects of worse quality of life. Impaired functional status was associated with mortality. Conclusion: Quality of life was impaired in patients starting haemodialysis. A higher C-reactive protein level level was a consistent independent predictor of the majority of worse quality of life. Transferrin saturation ≤ 20% was associated with worse physical component score of quality of life. Baseline quality of life was predictive of all-cause mortality and the primary outcome measure. EudraCT registration number: 2013-002267-25. Graphical abstract: [Figure not available: see fulltext.].
Author(s): Bhandari S, Parfrey P, White C, Anker SD, Farrington K, Ford I, Kalra PA, McMurray JJV, Robertson M, Tomson CRV, Wheeler DC, Macdougall IC
Publication type: Article
Publication status: Published
Journal: Journal of Nephrology
Year: 2023
Volume: 36
Pages: 1651-1662
Online publication date: 30/03/2023
Acceptance date: 01/01/2023
ISSN (print): 1121-8428
ISSN (electronic): 1724-6059
Publisher: Springer Science and Business Media Deutschland GmbH
URL: https://doi.org/10.1007/s40620-023-01571-6
DOI: 10.1007/s40620-023-01571-6
PubMed id: 36995528
Altmetrics provided by Altmetric
